Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Hepatic Internal Radiation and Ipilimumab/Nivolumab in Uveal Melanoma
NCT02913417Phase 2Unknown
- Start
- Oct 2016
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in Uveal melanoma (UM). Primary endpoint: Safety and tolerability of sequential selective internal radiation with Yttrium90 followed by immunotherapy at 5 years. Status: unknown.
02
Drugs
ipilimumabnivolumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02913417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913417.